Disease Science Footnotes/Bibliography

Bibliography

1.Mitchel, T., Geetha, M., James, E. V., Rebecca, H. R. & Judy, B. D. H. Oxidative stress and NLRP3-inflammasome activity as significant drivers of diabetic cardiovascular complications: therapeutic implications. (2018). https://www.frontiersin.org/articles/10.3389/fphys.2018.00114/full

2.Rameez, H., Nasir, J. & Sangdun, Choi. “The roles of the N. inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions The roles of the NLRP3 inflammasome in neurodegenerative and metabolic diseases and in relevant advanced therapeutic interventions. (2020). https://www.mdpi.com/2073-4425/11/2/131

3.Chi, T. et al. Specific NLRP3 inflammasome inhibitors: promising therapeutic agents for inflammatory diseases. (2021). https://www.sciencedirect.com/science/article/pii/S135964462100101X

4.David, M. H. Amyloid-β and Tau at the Crossroads of Alzheimer’s Disease. (2019). https://link.springer.com/chapter/10.1007/978-981-32-9358-8_16

5.Luwen, W. et al. Rab10 phosphorylation is a prominent pathological feature in Alzheimer’s disease. (2018). https://content.iospress.com/articles/journal-of-alzheimers-disease/jad180023

6.Pietro, A. & Laura, Cogli. “The role of rab proteins in neuronal cells and in the trafficking of neurotrophin receptors The role of rab proteins in neuronal cells and in the trafficking of neurotrophin receptors. (2014). https://www.mdpi.com/2077-0375/4/4/642

7.Kate, L., David, J. K., Tiago, F. O. & Flaviano, Giorgini. “Therapeutic targeting of R. Gtp. R. for A. disease Therapeutic targeting of Rab GTPases: Relevance for Alzheimer’s disease. (2022). https://www.mdpi.com/2227-9059/10/5/1141

8.Anca, I., Camilla, I. S., Vivianne, M., Georg, S. & Lars, Klareskog. “Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis Mechanisms leading from systemic autoimmunity to joint-specific disease in rheumatoid arthritis. (2017). https://www.nature.com/articles/nrrheum.2016.200

9.Na, L., Keshav, R. S. & Lihua, D. Role of NLRP3 inflammasome in rheumatoid arthritis. (2022). https://www.frontiersin.org/articles/10.3389/fimmu.2022.931690/full

10.Chengyu, Y., Jianqiao, F. & Boyi, L. The NLRP3 inflammasome: an emerging therapeutic target for chronic pain. (2021). https://link.springer.com/article/10.1186/s12974-021-02131-0

11.Fengxian, L. et al. The inflammasome as a target for pain therapy. (2016). https://academic.oup.com/bja/article-abstract/117/6/693/2671120

12.Mikkael, A. & Justin, Taylor. “Diagnosis and treatment of myelodysplastic syndromes: a review Diagnosis and treatment of myelodysplastic syndromes: a review. (2022). https://jamanetwork.com/journals/jama/article-abstract/2795886

13.Howard, S. O., Michael, H. & Drorit, Neumann. “The lower risk M. patient at risk of rapid progression The lower risk MDS patient at risk of rapid progression. (2010). https://www.sciencedirect.com/science/article/pii/S0145212610002821

14.Mengjia, H., Yukai, L., Songling, H. & Junping, Wang. “Inflammasomes and the maintenance of hematopoietic homeostasis: new perspectives and opportunities Inflammasomes and the maintenance of hematopoietic homeostasis: new perspectives and opportunities. (2021). https://www.mdpi.com/1420-3049/26/2/309

15.Bofeng, L., Arnaud, J. K. K., Tengchuan, J. & Jinhui, T. Pharmacological inhibitors of the NLRP3 inflammasome. (2019). https://www.frontiersin.org/articles/10.3389/fimmu.2019.02538/full

16.Weiming, O., Chuanshu, Huang. “Inflammation & a,  key event in cancer development Inflammation, a key event in cancer development. (2006). https://aacrjournals.org/mcr/article-abstract/4/4/221/284795

17.Do-Hee, K. & Young-Joon, Surh. “Dynamic roles of inflammasomes in inflammatory tumor microenvironment Dynamic roles of inflammasomes in inflammatory tumor microenvironment. (2021). https://www.nature.com/articles/s41698-021-00154-7

18.Ulrich, T. H., Hildegard, B., Olivier, B. & Sahil, A. Pyroptotic and necroptotic cell death in the tumor microenvironment and their potential to stimulate anti-tumor immune responses. (2021). https://www.frontiersin.org/articles/10.3389/fonc.2021.731598/full

19.Maria, G., Louis, B., Andreas, K., Aikaterini, H. & Panayotis, V. Ablation of NLRP3 inflammasome rewires MDSC function and promotes tumor regression. (2022). https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.889075/full?trk=public_post_comment-text

20.Maria, S., Efthimios, D., Georgios, M. H., Dimitrios, B. & Georgia, Xiromerisiou. “Neurodegeneration and inflammation—an interesting interplay in P. disease Neurodegeneration and inflammation—an interesting interplay in Parkinson’s disease. (2020). https://www.mdpi.com/1422-0067/21/22/8421

21.Yu-He, Y., Nai-Hong, C. & Hong-Bo, W. The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson’s disease. (2019). https://www.sciencedirect.com/science/article/pii/S1567576918307641

22.Yiming, Z., Rui, L., Lingpeng, Z., Buqing, F. & Tianhua, Yan. “Salidroside ameliorates P. disease by inhibiting N. pyroptosis Salidroside ameliorates Parkinson’s disease by inhibiting NLRP3-dependent pyroptosis. (2020). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288953/

23.Jonathan, D., Jesper, F. H. & Charles, A. Dinarello. “Pharmacologic inhibition of N. reduces the levels of α-synuclein and protects dopaminergic neurons in a model of P. disease Pharmacologic inhibition of NLRP3 reduces the levels of α-synuclein and protects dopaminergic neurons in a model of Parkinson’s disease. (2023). https://link.springer.com/article/10.1186/s12974-023-02830-w

 

Obesity

Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.

Learn More

Pain and Rheumatoid Arthritis

Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.

Learn More

Alzheimer's Disease

Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.

Learn More

Parkinson's Disease

Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.

Learn More

Cancer

Cancer occurs when normal cells become cancerous cells that multiply and spread. Cancer is the second most common cause of death in the U.S. However, fewer people die of cancer now than 20 years ago19. Halia is developing potential pathways to prevent the onset of cancer.
Learn More